Keytruda is an immunotherapy drug that is prescribed to cancer patients and is used to treat different types of cancer. It was first approved by the FDA in 2014 for the treatment of advanced or ...
At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA demonstrated a 49% reduction in the risk of ...
BioInvent International (STO:BINV)24% confirmed ORR (including complete response) in heavily pretreated patients (n=25) with advanced ovarian cancer who received BI-1808 and KEYTRUDA - multiplying by ...
Dallas and Austin are part of a worldwide clinical trial underway to find a more effective treatment to lower the recurrence of melanoma or high-risk skin cancer. It involves a highly advertised drug ...
EU CHMP recommends approval of Merck’s Keytruda plus Padcev as perioperative treatment for adults with cisplatin-ineligible resectable muscle-invasive bladder cancer: Rahway, Ne ...
Moderna and Merck present 5-year data for intismeran autogene in combo with Keytruda in patients with high-risk stage III/IV melanoma following complete resection at 2026 ASCO mee ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results